Fig. 7: BTNL2 was strongly expressed in some of PD-1 inhibitor treatment-resistant lung cancer samples. | Nature Communications

Fig. 7: BTNL2 was strongly expressed in some of PD-1 inhibitor treatment-resistant lung cancer samples.

From: Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells

Fig. 7

a, b Immunohistochemistry staining of BTNL2 and Napsin A expression in lung adenocarcinoma samples was shown (serial section of slices was stained with anti-BTNL2 and anti- Napsin A). Scale bar = 202 μm for a, Scale bar = 50 μm for b. “P” represents para-cancerous tissue; “C” represents cancer tissue. c Sketch Map of BTNL2 blockage in the TME was shown, that tumour cell-expressed BTNL2 promotes γδT17 cells differentiation, which recruits MDSCs into TME to inhibit the cytotoxic function of CD8 + T cells. Blockage of BTNL2 by mAb abolishes the γδT17 cells differentiation and subsequent recruitment of MDSCs, which re-activates CD8 + T cells for the tumour-cytotoxic function. Data in a, b are representative of three independent experiments.

Back to article page